Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes.

Lee HN, Kim TH, Lee SJ, Cho WY, Shim BS.

Int Braz J Urol. 2014 May-Jun;40(3):356-66. doi: 10.1590/S1677-5538.IBJU.2014.03.09.

6.

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.

Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.

PMID:
18817961
7.

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.

Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.

PMID:
22297243
8.

The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.

Salah Azab S, Elsheikh MG.

Aging Male. 2015 Jun;18(2):89-92. doi: 10.3109/13685538.2014.967672. Epub 2014 Oct 8.

PMID:
25295872
9.
11.

Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.

El-Tatawy H, Gameel T, El-enen MA, Hagras A, Mousa A, El-Bahnasy AH, Raheem AA, Abu-dewan K.

Arch Ital Urol Androl. 2015 Sep 30;87(3):238-42. doi: 10.4081/aiua.2015.3.238.

12.

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.

Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L.

Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7.

PMID:
20487046
13.

Measuring the improvement in health-related quality of life using King's health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study.

Kim JH, Choi H, Sun HY, Doo SW, Yoon JH, Yang WJ, Yoo BW, Kim JM, Kwon SS, Song ES, Lee HJ, Lim IS, Song YS.

BMC Urol. 2014 Aug 6;14:60. doi: 10.1186/1471-2490-14-60.

14.
15.

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.

Urology. 2013 Sep;82(3):667-73. doi: 10.1016/j.urology.2013.05.005. Epub 2013 Jul 19. Erratum in: Urology. 2014 Mar;83(3):684.

PMID:
23876588
16.

Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Yu HJ, Lin AT, Yang SS, Tsui KH, Wu HC, Cheng CL, Cheng HL, Wu TT, Chiang PH.

BJU Int. 2011 Dec;108(11):1843-8. doi: 10.1111/j.1464-410X.2011.10233.x. Epub 2011 May 18.

17.

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.

Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A.

Eur Urol. 2013 Jan;63(1):158-65. doi: 10.1016/j.eururo.2012.07.003. Epub 2012 Jul 17.

PMID:
22831853
18.

Effect of selective alpha-blocker tamsulosin on erectile function in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Shelbaia A, Elsaied WM, Elghamrawy H, Abdullah A, Salaheldin M.

Urology. 2013 Jul;82(1):130-5. doi: 10.1016/j.urology.2013.03.026. Epub 2013 May 25.

PMID:
23711438
19.

Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey.

Kim JH, Park JY, Oh MM, Lee JG, Kwon SS, Bae JH.

Int J Clin Pract. 2012 Dec;66(12):1209-15. doi: 10.1111/j.1742-1241.2012.02985.x.

PMID:
23163501
20.

The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.

Lee YC, Liu CC, Juan YS, Wu WJ, Li WM, Yeh HC, Wang CJ, Huang CN, Huang CH, Huang SP.

Int J Clin Pract. 2013 Apr;67(4):356-62. doi: 10.1111/ijcp.12086. Epub 2013 Feb 14.

PMID:
23409734

Supplemental Content

Support Center